We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+39.15%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$831M
AUM Growth
+$203M
Cap. Flow
-$333M
Cap. Flow %
-40.1%
Top 10 Hldgs %
41.06%
Holding
181
New
59
Increased
25
Reduced
46
Closed
41

Top Buys

Rank Stock Value
1
RCKT icon
Rocket Pharmaceuticals
RCKT
+$11.9M
2
AKRO
Akero Therapeutics
AKRO
+$9.31M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$9.18M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$6.77M
5
IMVT icon
Immunovant
IMVT
+$6.73M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$11.5M
2
INSM icon
Insmed
INSM
+$7.55M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$6.95M
4
BHVN icon
Biohaven
BHVN
+$6.68M
5
BMEA icon
Biomea Fusion
BMEA
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
101
DELISTED
Terns Pharmaceuticals
TERN
$832K 0.1%
165,480
-150,000
-48% -$952K
JSPR icon
102
Jasper Therapeutics
JSPR
$21M
$788K 0.09%
112,509
– –
ELEV
103
DELISTED
Elevation Oncology
ELEV
$777K 0.09%
1,171,939
+22,449
+2% +$22.7K
TYRA icon
104
Tyra Biosciences
TYRA
$1.9B
$663K 0.08%
48,170
– –
IMUX icon
105
Immunic
IMUX
$190M
$662K 0.08%
45,000
-20,000
-31% -$384K
LLY icon
106
Eli Lilly
LLY
$1.02T
$659K 0.08%
+1,227
New +$632K
PRQR icon
107
ProQR Therapeutics
PRQR
$243M
$614K 0.07%
472,625
– –
AUTL
108
Autolus Therapeutics
AUTL
$397M
$612K 0.07%
262,694
+2,607
+1% +$7.43K
COGT icon
109
Cogent Biosciences
COGT
$6.65B
$612K 0.07%
62,766
– –
IMTX icon
110
Immatics
IMTX
$1.18B
$568K 0.07%
49,031
– –
KOD icon
111
Kodiak Sciences
KOD
$2.6B
$563K 0.07%
312,881
+250,354
+400% +$883K
KPTI icon
112
Karyopharm Therapeutics
KPTI
$43.5M
$536K 0.06%
26,667
– –
ANEB
113
DELISTED
Anebulo Pharmaceuticals
ANEB
$504K 0.06%
157,862
+1,659
+1% +$4.6K
TCON
114
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$492K 0.06%
138,277
– –
HOOK
115
DELISTED
HOOKIPA Pharma
HOOK
$327K 0.04%
53,078
-6,922
-12% -$50.8K
TARA icon
116
Protara Therapeutics
TARA
$220M
$315K 0.04%
188,664
– –
MORF
117
PUT
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$296K 0.04%
+129
New +$6.77K
TGTX icon
118
TG Therapeutics
TGTX
$7.96B
$272K 0.03%
+32,547
New +$454K
PTCT icon
119
PTC Therapeutics
PTCT
$5.68B
$243K 0.03%
+10,862
New +$404K
VRNA
120
DELISTED
Verona Pharma
VRNA
$214K 0.03%
318,591
+4,914
+2% +$94.6K
STOK icon
121
CALL
Stoke Therapeutics
STOK
$1.8B
$197K 0.02%
500
-214,700
-100% -$1.41M
MREO
122
Mereo BioPharma
MREO
$54.7M
$191K 0.02%
591,676
-300,000
-34% -$398K
CMMB
123
Chemomab Therapeutics
CMMB
$11.4M
$191K 0.02%
53,348
– –
CRSP icon
124
CALL
CRISPR Therapeutics
CRSP
$4.73B
$177K 0.02%
39
-199,961
-100% -$10.3M
SCPH
125
DELISTED
scPharmaceuticals
SCPH
$133K 0.02%
18,647
-131,353
-88% -$1.03M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Ikarian Capital held 181 positions worth $831M, up 32% from $628M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Ikarian Capital withdrew a net $333M in Q3 2023, closing 41 positions and reducing 46 holdings. Its most notable exit was Merck, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 44% a quarter earlier.

Against the trend, Ikarian Capital opened a new position in Rocket Pharmaceuticals worth $13.4M.

  • Ikarian Capital's largest Q3 2023 buy was Rocket Pharmaceuticals: 654,726 shares worth $13.4M.
  • Ikarian Capital added most to Crinetics Pharmaceuticals in Q3 2023, an estimated $6.55M increase.
  • Ikarian Capital's biggest Q3 2023 reduction was Insmed, cutting an estimated $7.55M.
  • Ikarian Capital fully exited Merck in Q3 2023, selling an estimated $11.5M.
  • Ikarian Capital's ten largest holdings make up 41% of its $831M portfolio in Q3 2023.
  • Ikarian Capital opened 59 new positions and closed 41 in Q3 2023.
  • Ikarian Capital's portfolio value rose 32% quarter-over-quarter to $831M.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.